

## INDEX

Page references followed by an italicized-*fig.* indicate graphs or other illustrations. Page references followed by an italicized *t.* indicate tables.

- active surveillance, 101, 152, 261, 279, 286, 296, 309–310, 320, 331
- Adapted Interdependence Model, 70, 71 *fig. 4.1*; cancer care provision and, 76–77; communal coping in, 77–79, 80; as hypothesis generation basis, 79–80; individual- / couple-level factors affecting, 72–75; recommendations, 80; transformation of motivation in, 76
- African American GBM, 15, 73, 151, 233
- African American men, 287–288
- age, 72, 151, 152, 154, 266, 287
- aging, premature, 24, 107–108
- AIDS. *See* HIV/AIDS
- AIDS Council of New South Wales, 281
- Aizer, A. A., 69
- alcohol use, 233
- Allensworth-Davies, Donald, 20 *t. 1.3*
- alternative diet therapy, 294
- American Association of Sexuality Educators, Counselors, and Therapists, 64
- American Cancer Society, 151
- American Society of Clinical Oncology (ASCO), 158–160, 159 *t. 9.1*
- Amiel, Gilad E., 295
- anal plugs, 186, 321
- anal sex: erectile dysfunction and, 41, 59–60, 61, 105; erectile firmness required for, 39; GBT conceptualization of, 237; HCP discussions about, 142; health benefits of, 287; insertive partner in (top), 228, 325, 330; penis size and, 44; as prostate cancer risk factor, 15, 308–309; after prostate cancer treatment, 24–25, 38, 169; quality of life considerations and, 155; radiotherapy vs. radical prostatectomy effects and, 228; receptive partner in (bottom), 24–25, 38, 228, 321, 328; role shifts in, 42, 45–46, 61–62, 105, 155–156, 223–224, 227; sexual aids/toys assisting with, 171–172; sexual rehabilitation research neglecting, 181–182
- androgen deprivation therapy (ADT), 164–165, 166, 320
- Aneros (sex toy), 172
- anger, 301
- anilingus (rimming), 165
- anodyspareunia, 320
- antibiotics, 313
- antiretroviral (ARV) treatment, 15–23, 79, 109, 320
- anxiety, 3, 103, 219, 237–238, 296
- aporia, 320
- Armour Knight (dildo), 170
- Asencio, M., 16 *t. 1.2*
- Australia: health equity in, 118; Malecare collaborations in, 250; prostate cancer rates in, 151, 259; research studies including citizens of, 40, 87–88, 102, 103; same-sex marriage legalized in, 175
- Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, 50, 145

- Australian National Prostate Cancer Conference, 266–267
- benign prostatic hyperplasia (BPH), 293, 305, 320–321
- Berer, Marge, 258
- Bergman, J., 210
- bicalutamide, 321
- biopsy: active surveillance and, 310; decision-making regarding, 312–313; defined, 321; gay sex following, 314; personal experiences, 274, 276, 284–286, 293–294, 298, 312–313, 314; SDM model and, 304; side effects of, 286, 293, 298
- biopsychosocial sexuality, 56–60
- bisexuality, 321
- bisexual men, 118, 252. *See also* gay/bisexual men (GBM); GBM with prostate cancer; lesbian/gay/bisexual/transgender (LGBT) populations
- black men, 156, 293. *See also* African American GBM
- Blank, Thomas O., 100–101
- bleeding, 286, 293, 298
- blood workups, 312
- blow job, 165
- body image, 107, 156, 203
- Boehmer, U., 151, 154
- bother, 153–154, 174–175, 321
- bottoms, 228, 321, 328
- bowel function bother, 153
- bowel incontinence, 201, 210, 218, 219, 220, 321
- brachytherapy, 153, 274–275, 294, 296, 321
- Brass, Perry, 284–289
- Brazil, 118
- breast cancer, 133
- buffering hypothesis, 211
- California, 109
- California Health Interview Survey, 15, 151, 154, 305
- California State University, San Bernardino, 72
- Canada, 155, 175, 250
- cancer: sexual minority risk factors, 87. *See also* prostate cancer
- Cancer and the LGBT Community* (Amiel et al.), 295
- cancer care providers. *See* healthcare professionals (HCPs)
- Cancer Council (Australia), 281
- Cancergraph, 256, 256n
- Capistrant, B. D., 18 *t. 1.2*
- Caribbean islands, 151
- case-control study, 321
- casual sex, 106, 187, 190
- Caverject injections, 105, 192, 321. *See also* intracavernous injection (ICI)
- Centers for Disease Control and Prevention (CDC), 3, 13, 305
- Centers for Medicare and Medicaid Services (CMS), 316
- Chance, Travis, 126
- chemotherapy, 288
- Christie, D. R., 153
- chronic disease, 321
- Cialis, 181, 183, 187, 192–193, 293
- cisgender, 321

- civic activities, 203
- civil union recognition, 106
- Clark, J., 20 *t.* 1.3
- climacturia, 38, 49, 62, 321–322, 331
- clinical trials, 254
- CloneAWilly.com, 170
- Cobra Libre (vibrator), 171
- cock rings, 183, 187, 301, 322
- cohort studies, 322
- coitus, 322
- communal coping, 70, 73, 77–79, 80
- community activities, 203
- community connectedness, 90–91
- comorbidity, 322
- condoms, 25, 109, 119
- controlled studies, 322
- CopyMeKits.com, 170
- counseling, 62, 63–64, 180
- couplehood, 69–70, 322
- Cowper's glands, 322
- CreateaMate.com, 170
- cryotherapy, 294
- cultural background, 72
- cultural competency, 125–126, 143–145, 152
- cure, 101
- cyber-knife treatment, 294
- cycling, 308–309
  
- Da Vinci robot, 275, 278, 294, 322
- Dayton, Mark, 311
- decisional regrets, 153, 239, 304, 322
- decision making. *See* shared decision-making (SDM) model
  
- Depend, 322
- depression, 3, 93, 103, 104, 193, 219, 224–226, 275, 277, 288, 296
- Deuce (harness), 170
- diagnosis, 322
- diet, 15, 152, 287, 294
- digital rectal exam (DRE), 259–260, 273, 288, 293, 296, 322
- dildos, 169, 170
- discrimination: community connectedness and, 90–91; defined, 322; by families of origin, 90–91; fear of, 4, 55, 78, 134; HCPs and, 75, 78, 133, 175; HIV infection and, 110; institutionalized, 90, 92; interdependence theory and, 68, 72; legal protections against, 175; as minority status issue, 24; stress caused by, 79; TGW fear of, 235. *See also* heterosexism; homophobia; stigmatization
- distress, psychological, 79, 87, 153, 157, 164
- doctor-patient communication, 15. *See also* healthcare professionals (HCPs)—GBM communication with
- Doran, D., 17 *t.* 1.2
- Dowsett, Gary W., 16 *t.* 1.2, 21 *t.* 1.3, 61–62, 258–270, 295
- Doyle, D. M., 93
- Drescher, J., 100–101, 295
- Drummond, Murray, 116–117
- dyadic coping, 70, 76–77, 92
- dyadic couplehood, 69
  
- education, 72
- educational resources, 24
- ejaculate, blood in, 314

- ejaculate loss: emotional reactions, 57;  
gay sex/sexuality and, 24, 48, 55;  
multiorgasmic capabilities enhanced  
by, 166; personal experiences,  
265–266, 268, 298–299; as prostate  
cancer treatment side effect, 24, 39,  
47–48, 55, 56, 102, 275; radiotherapy  
vs. radical prostatectomy, 218, 221,  
227–228; relationships and, 55, 57.  
*See also* non-ejaculatory orgasms
- ejaculation, 322; retrograde, 299
- ejaculatory bother, 87–88
- Elator (penile support device), 172
- e-mail, 304
- EMBASE, 13
- emotional reactions, 56
- employment, 200, 204
- epidemiology, 322, 325
- epigenetic markings, 93
- equipoise, 229
- erectile dysfunction: anal sex and, 25,  
59–60, 61, 105; bother from, 174–175;  
condom use and, 109; defined,  
322–323; gay identities and, 38,  
41–42; gay sex/sexuality and, 55, 56,  
57; illness intrusiveness and, 203;  
masculine identity and, 111, 296;  
partnerships and, 174–175; personal  
experiences, 264, 292–293, 295–  
296, 298; as prostate cancer  
treatment side effect, 3, 25, 39, 55, 56,  
57, 102, 153, 164–165, 261; quality of  
life considerations and, 155; radio-  
therapy and, 289; radiotherapy vs.  
radical prostatectomy, 218, 219,  
221–223, 227, 228; relationships and,  
39, 44–46, 55, 57; sexual aids/toys  
assisting with, 167–173, 186; sexual  
disqualification because of, 44–46;  
support group discussions about,  
220, 301
- erotic electrostimulation, 183–187
- eroticization, 174
- estrogen therapy, 165–166, 167, 235, 237
- ethnicity, 152
- eunuch, 323
- Europe, northwestern, 151
- Evans, Andrew, 288
- familial support, 24, 25, 74–75, 90–91
- family, “chosen,” 91–92, 321
- Family and Medical Leave Act (FMLA;  
U.S.), 125
- family history, 316
- fatty diet, 15
- feces, blood in, 286
- fellatio (blow job), 165
- Fergus, K. D., 16 *t. 1.2*
- finasteride (Propecia), 15, 285, 323
- Flomax, 297, 298
- Florida, 151
- Food and Drug Administration (FDA),  
305
- foreplay, 60, 169
- “forgetting,” 104
- function, 321, 323
- funfactory.com, 171
- gay/bisexual men (GBM): defined, 323;  
health promotion strategies for, 119;  
HIV/AIDS deaths among, 3;  
pharmaceutical industry and, 253;  
prostate cancer diagnoses among, 12;  
prostate cancer risk among, 2, 15–23;

- prostate cancer screenings among, 12, 24, 305; research literature on, 12; sex toy use of, 166–167; sexually promiscuous stereotype of, 119. *See also* African American GBM; GBM with prostate cancer; GBM with prostate cancer—radiotherapy vs. radical prostatectomy effects
- Gay City News*, 284
- gay communities: HIV/AIDS activism of, 248; sexual cultures of, 107–108, 187
- gay couples, 323
- gay identities, 38; ejaculate loss and, 47–48; erectile dysfunction and, 41–42, 44–46; “forgetting,” 104; penis size reduction and, 42–44; sexuality and, 108; as social, 104, 107–108; urinary incontinence and, 48–49
- gay male culture, 43–44
- Gay Man’s Guide to Prostate Cancer, A* (ed. Perlman and Drescher), 295
- gay men with prostate cancer: barriers/concerns facing, 126–127; emotional reactions of, 300; heteronormativity and healthcare needs of, 123, 294–295; HIV infection and, 109–110; as “invisible diversity,” 100–101, 110; legal/ethical considerations, 124–125; liminality of, 100–102; literature aimed at, 295; men’s health promotion and, 117–119; personal experiences, 292, 294–295; relationship and, 106–108, 120–121; research/clinical recommendations, 110–112; sex/sexuality of, 103–106; single, 125–126, 164; support groups, 246, 296
- gayness, as social identity, 104, 323
- gay pride, 323
- gay psycho-oncology, 256
- gay relationships, 106–108, 120–121
- gay rights, 124
- gay sex/sexuality, 100; HCPs and, 132, 140–143, 145; HIV infection and, 109–110; post-biopsy, 314; after prostate cancer treatment, 103–106, 111–112, 121–123, 173; sexual aids/toys and, 187; as social practice, 102, 107–108. *See also* anal sex
- GBM couples: communication in, 58–60, 68, 74–75; opening relationships in, 62–63; protectiveness in, 63–64; sexual losses and, 57–58
- GBM with prostate cancer: communication with HCPs (*see* healthcare professionals (HCPs)—GBM communication with); comprehensive care models for, 232 (*see also* GBT comprehensive prostate cancer care model); demographic/medical information for, 205 *t. 12.1*; HIV-positive, 24; post-treatment quality of life, 12, 133; psychological adjustment of (*see* psychological adjustment); rates of, 13–14, 151; research literature on, 12, 14 *t. 1.1*, 55–56, 218, 268–269; sexual recovery of, 165; single, 157, 173, 200–201, 203; social support for, 25, 73–74, 91, 156–157; survivorship roles of, 150; treatment decision making by, 154–157; as underresearched, 39–40, 55, 69–70, 80, 86, 100, 175. *See also* illness intrusiveness and social support
- GBM with prostate cancer—radiotherapy vs. radical prostatectomy effects: differences, 227–228; future research in, 228; physical (sexual) changes,

- 219, 220–224, 222–223 *t.* 12.1, 227–228; psychological (emotional) changes, 219–220, 224–227, 225–226 *t.* 12.2, 228–229; research studies on, 218, 219–220; SDM model and, 229–230; similarities, 227, 228–229
- GBT comprehensive prostate cancer care model, 234 *fig.* 14.1; clinical care implications, 240–241; need for, 232–233; post-treatment/survivorship, 238–240; screening/diagnosis, 233–235; treatment, 236–238
- gender, 72, 118
- gender identity, 150, 152, 158, 237
- gender minorities, 323–324
- gender-reassignment surgery, 3, 14, 164, 235, 324
- genetics, 287–288, 305
- genital skin sensitivity, 165–166
- Giuliani, Rudolph, 294, 296
- Gleason score, 261, 275, 285–286, 288, 289, 324
- Global Prostate Cancer Alliance, 251, 255
- golden showers, 301
- Goldstone, S. E., 24, 169
- gonorrhoea, 15
- Gore, J. L., 210
- grief, 56, 59, 220, 226–227, 301, 308, 316
- “grilled cheese effect,” 289
- grounded theory, 324
- group interventions, 64
- group sex, 106
- guilt, 62
- gynecomastia, 153, 156, 157, 288, 324
- hair loss treatments, 15
- hand job, 165
- Hart, Tae L., 21 *t.* 1.3, 155–156
- Hartman, M. E., 59, 61, 62, 63
- health, 200, 204
- healthcare needs, 86, 90, 91–92, 123, 235
- healthcare professionals (HCPs), 211–212; GBM cultural competency needed from, 143–145, 158–160, 159 *t.* 9.1; heteronormativity and, 123, 132, 137–138, 143–144, 175, 248; importance of, 68, 76–77; nondiscriminatory clinical environment needed from, 80, 145; prejudice and, 78, 152; sexual concerns increasingly addressed by, 133
- healthcare professionals (HCPs)—GBM communication with: by e-mail, 304; facilitators of, 132, 140, 142–143; about gay sex/sexuality, 132, 140–143, 145; heteronormativity and, 132, 137–138, 294–294; illness intrusiveness and, 212; personal experiences, 284–289, 294–295, 311–312, 313; recommendations, 143–145, 158–160, 159 *t.* 9.1; research studies, 134–136, 135 *t.* 8.1; sexual orientation disclosures, 133–134, 138–140, 144–145, 236–237; sexual rehabilitation information access and, 188, 193–194; shared decision making and, 152, 157, 229, 236–237, 304
- health disparities, 324
- health education, 117–118
- Health Insurance Portability and Accountability Act (HIPAA), 324, 326
- health-related quality of life (HRQOL), 201, 324

- Healthy People 2020, 13
- hegemony, 324
- Henderson, Ross, 272–282
- heterocentrism/heteronormativity:  
defined, 324–325; GBM sexual rehabilitation/recovery and, 181–182; HCPs and, 132, 133–134, 137–138, 143–144, 175, 248; pharmaceutical industry marketing and, 253; in prostate cancer literature, 105, 106, 123, 132, 137, 277; in prostate cancer research, 100
- heterosexism, 55, 261–262, 292, 294–295, 325. *See also* discrimination; homophobia; stigmatization
- heterosexual coping, 69–70, 73, 78, 91
- heterosexuality, 3, 325; assumptions of (*see* heterocentrism/heteronormativity)
- heterosexual marriage, 69
- heterosexual men: anal sex and, 61, 105; emotional reactions of, 300, 301; interdependence theory and, 73; long-term vs. short-term outcomes of prostate cancer treatments for, 219; masculine identity and, 63; openness to discussing sexual practices, 59; with postmenopausal partners, 57; pro-inflammatory biomarkers among, 93; PSA testing among, 15, 305; research focused on, 3, 81, 93; sex toy use of, 166–167; as sexually promiscuous, 45, 119; single, 203; social support of, 73, 74, 91, 201, 301; survivorship roles of, 150. *See also* sexual rehabilitation/recovery—GBM vs. heterosexual men
- HIV/AIDS: activism, 248; ARV treatments for, 79; cancers resulting from, 19, 320; deaths from, 3; defined, 325; diagnosis of, and prostate cancer risk, 15–23, 152, 233; epidemic, 309; gay sex/sexuality and, 109–110; as GBM healthcare challenge, 92; health messages regarding, 119; interdependence theory and, 70; pharmaceutical industry and, 253; safe sex and, 259; transmission risk, 25
- homonegativity, 326
- homophobia, 70, 73, 110, 119, 123, 133, 175, 238. *See also* discrimination; heterosexism; stigmatization
- homosexuality, 309, 325
- hormone therapy, 3, 14, 156, 235, 288, 294, 325
- Horn, Mark, 286, 289
- hot flashes, 156, 288
- hotoctopuss.com, 171
- Hoyt, Michael A., 79
- Hu, Jim, 239, 289
- Huntley, A. L., 201
- Iceland, 250
- illness intrusiveness, 200, 202
- illness intrusiveness and social support: future research in, 211–212; IITF and, 200, 202–203; moderation analyses, 206–208, 207 *fig. 12.1*, 208 *fig. 12.2*, 209 *t. 12.3*; relationship status and, 200, 203–204, 206 *t. 12.2*, 208–212; research literature on, 201–202; as underresearched, 200
- Illness Intrusiveness Ratings Scale (IIRS), 203–204
- Illness Intrusiveness Theoretical Framework (IITF), 200, 202–203, 210, 325

- immune function, 78, 79
- immunodeficiency, 19–23, 325
- impotence, 325. *See also* erectile dysfunction
- incidence, 325
- inclusion/exclusion criteria, 325
- incontinence, 3, 48–49, 102, 155, 218, 276. *See also* bowel incontinence; urinary incontinence
- inflammation, 79, 93
- information sharing, 300, 305
- insertive partner, 325
- insomnia, 238
- interdependence theory, 70, 73, 326. *See also* Adapted Interdependence Model
- internalized homonegativity, 326
- Internet, 180, 256
- intracavernous injection (ICI), 167–168, 169, 326. *See also* Caverject injections
- Inventory of Socially Supportive Behaviors, 204
- Iran, 118
- Ireland, 118
  
- Kamen, Charles, 72, 157
- Kaposi's sarcoma, 320
- Kegel exercises, 326
- Kennedy, Anthony, 124, 125
- Kübler-Ross, Elisabeth, 308
- Kukula, K. C., 174
  
- lassoes. *See* cock rings
- latex accessories, 186
- Latini, D., 56, 60–61, 63
- Lee, T. K., 17 *t.* 1.2, 20 *t.* 1.3, 189
  
- lesbian/gay/bisexual/transgender (LGBT) populations: community connectedness, 90–91, 92; defined, 323, 326; HCPs and sexual concerns of, 133; health care disparities affecting, 24; healthcare environment recommendations for, 158–160, 159 *t.* 9.1; heterocentrism and, 324–325; psychosocial commonalities among, 251–252; research literature on, 13; support groups, 252; as underresearched, 3–4
- lesbians, 133, 252
- Levitra, 181, 193
- Lewis, M. A., 70, 71 *fig.* 4.1
- LGBT psycho-oncology, 256
- LGBTQI rights, 116, 124, 126
- libido: defined, 326; reduced, 39, 55, 57, 102, 121–123, 153, 165, 174
- liminality, 100–102, 326
- Limon, Ricardo, 284
- Lubben Social Network Index, 204
  
- magnetic resonance imaging (MRI), 286–287, 312, 326
- Malecare: collaborations of, 250–251, 255–256; founding of, 246–249, 299; innovative programming of, 256; mission goal of, 254, 256; National LGBT Cancer Project founded by, 252; as national organization, 249–250; personal experiences, 296; pharmaceutical industry outreach of, 252–253; research programs of, 220, 253–255, 256; support group model of, 249–250, 254
- Mandela, Nelson, 264
- marginalization, 326



- Margolies, Liz, 72
- marriage, 69, 77, 79, 124–125
- masculine identity, 3, 24, 39, 42, 44; age and, 154; coping strategies and, 74; erectile dysfunction and, 111; hegemonic construction of, 118; sexuality and, 59
- “masculinities,” 111, 118
- masculinity studies, 111
- massage, 237
- masturbation, 105–106, 169, 237
- masturbatory aids, 171
- McCarthy, B. W., 203
- McNamara, M., 233
- meat diet, 287
- medical aids, 180, 181, 183, 188, 189–193, 275
- Medicare, 316
- MEDLINE, 13
- Mehnert, A., 210, 239
- Melbourne (Australia), 260, 281
- men’s health promotion, 117–119
- mental health problems, 92, 102–103, 133
- men who have sex with men (MSM):  
HCP marginalization of sexual needs of, 137–138; numbers of, in U.S., 3; prostate cancer risk among, 2, 151; PSA testing among, 24; survivorship roles of, 150; as underresearched, 3, 151, 219. *See also* gay/bisexual men (GBM)
- Millar, Brett M., 79
- minority stress theory, 86, 87, 88–90, 92–94, 326
- Mitteldorf, Darryl, 21 t. 1.3, 246–247, 248–249, 296, 299
- Molix, L., 93
- mood swings, 288
- motivation, transformation of, 76
- Motofei, I. G., 20 t. 1.3
- Moving On study, 102
- Mt. Sinai Hospital (New York), 286, 288, 289
- multiple minority statuses, 152
- multiple orgasms, 166–167, 172
- MyChart, 326
- National LGBT Cancer Network, 72
- National LGBT Cancer Project, 252
- National Nursing Oncology Conference, 116–117
- Negative Interactions, 204
- neovagina, 172
- New York City, 247–248
- New York City Gay and Lesbian Center, 296
- New Zealand, 175, 278
- Ng, H., 233
- Nobert, Craig, 286, 288–289
- non-ejaculatory orgasms, 3, 38, 39, 265–266. *See also* ejaculate loss
- non-Hodgkin’s lymphoma, 320
- nonmonogamy, 106
- Obama, Barack, 124n
- Obergefell v. Hodges*, 124, 125
- obesity, 287
- observational studies, 326–327
- oncology, 327
- online support groups, 25
- opening relationships in, 106

- oral sex, 42, 60, 105–106, 165, 169, 237, 327
- orchidectomy, 3, 14, 327
- orgasms, 172; absence of, 164; changes in, following prostate cancer treatments, 166–167, 265–266; defined, 327; radiotherapy vs. radical prostatectomy, 227. *See also* non-ejaculatory orgasms
- outness, 327
- Out with Cancer groups, 252
- ovariectomy, 327
- Ovid, 13
  
- panic symptoms, 238
- partnerships: cancer survivorship and, 69; illness intrusiveness and, 200–201; sexual recovery role of, 165, 174–175
- patient buy-in, 304
- patient-centered healthcare, 312
- PDE5 inhibitor drugs, 105, 169, 181, 190, 192, 193, 327. *See also* Cialis; Levitra; Viagra
- pelvic floor rehabilitation, 62, 327
- pelvic lymphadenectomy, 236
- penile implants, 105, 169, 180, 181, 187, 191–192, 327
- penile injections, 180, 181, 190–191, 192, 193
- penile prosthesis, external (dildo), 170
- penile sleeves, 171–172
- penile support device, external, 172
- penis-casting products, 170
- penis size reduction, 38, 39, 42–44, 156, 219, 220–221, 227, 228–229
- Perlman, Gerald, 100–101, 292–302
- personal development, 200, 203
- Perz, Janette, 19 *t.* 1.2, 23 *t.* 1.3, 75, 145–146
- Pfizer, 295
- pharmaceutical companies, Malecare work with, 252–253
- phosphodiesterase type 5 inhibitor drugs. *See* PDE5 inhibitor drugs
- polyamorous relationships, 69
- potency, 327
- prejudice, 68, 72, 75, 78, 79, 90, 91, 152
- prevalence, 327
- Propecia, 15
- prostate: defined, 327–328; enlarged, 274, 285 (*see also* benign prostatic hyperplasia (BPH)); as erogenous zone, 39, 46, 122; loss of, 24; physical trauma to, and PSA testing, 24
- prostate cancer: as “couple’s disease,” 322; deaths from, 287; defined, 328; fear of recurrence, 267, 268; localized/early stage, treatment options for, 152–153, 236; physiological/psychological demands of, 86; predicting progression of, 287; rates of, 2–3, 13–14, 151, 259; risk factors for, 15, 151–152, 287, 305, 308–309; survival rates, 267–268, 309; testing age, 273. *See also* gay men with prostate cancer; GBM with prostate cancer
- prostate cancer diagnosis/diagnoses: comprehensive care model for, 233–235; emotional reactions, 219–220, 284, 294, 299, 300, 308; faulty, 288; perceptions of, 72, 74; personal experiences, 258–260, 272–274, 278, 284–289, 292–294, 306–314; rates of, 2, 3, 13–14; shared

- decision-making (SDM) model used following, 304 (*see also* shared decision-making (SDM) model)
- Prostate Cancer Foundation of Australia (PCFA), 50, 145, 250, 282
- prostate cancer screenings: comprehensive care model for, 233–235; rates of, 15; research literature on, 15. *See also* prostate-specific antigen (PSA) testing
- prostate cancer treatments: access to, 90–91; challenges of, 24–25; comprehensive care model for, 236–238; culturally competent, 92, 125–126, 158–160, 159 *t. 9.1*; decision-making regarding, 294–297, 302, 304 (*see also* shared decision-making (SDM) model); five-year survival rates after, 3; gay sex/sexuality following, 103–106, 121–123; GBM dissatisfaction with, 133, 193–194; illness intrusiveness and, 202–203; negative effects of, 3, 38–39, 78, 101–103, 152–156, 237–238, 275–276 (*see also* sexuality, post-prostatectomy); perceptions of, 68, 72, 74; phases of, 232; psychological effects of, 24, 86; sexual function changes following, 165–167; sexual recovery following, 164 (*see also* sexual rehabilitation/recovery); treatment options, 152–153, 236, 274–275. *See also* brachytherapy; prostatectomy; radiotherapy
- prostatectomy: anal sensitivity following, 61; average age for, 266; celebrities opting for, 294; decision-making regarding, 260–262, 278–279, 288–289, 297; defined, 328; erectile dysfunction following, 164, 261; orgasmic changes following, 166–167; personal experiences, 259, 262–263, 280; prognosis for recovery/survival following, 261; regrets following, 153, 239, 304, 322; as treatment option, 275; urinary incontinence following, 261. *See also* GBM with prostate cancer—radiotherapy vs. radical prostatectomy effects; sexuality, post-prostatectomy
- prostate massage, 287
- prostate-specific antigen (PSA), 153–154
- prostate-specific antigen (PSA) testing, 15, 24, 328; active surveillance approach and, 296; average age for, 293; as controversial, 288, 305, 306; in GBM, research needs for, 316–317; GBM vs. heterosexual male rates of, 305, 317; HIV infection and, 109; personal experiences, 259–260, 268, 273, 274, 282, 284–286, 292, 293, 306–307, 307 *fig. 20.1*, 308, 309–310, 313–314; research studies involving, 109; SDM model and, 304, 305–306
- prostatitis, 285, 305, 313
- prosthesis, 328. *See also* penile implants
- protectiveness, 58–59, 63–64, 69
- proton beam therapy, 294
- psychiatric morbidity, 233
- psychological adjustment: contributors to, 89 *fig. 8.1*, 90–92; epidemiological surveys of, 87–88; models of, 86, 87; research directions for, 92–94; understanding factors behind, 88–90
- psychological interventions, 93
- psychotherapy, 289
- PsycINFO, 13
- PubMed, 13
- Pulse (vibrator), 171

- quality of life, 3, 87, 88, 93, 133, 153, 154, 174, 201, 233. *See also* health-related quality of life (HRQOL)
- Queensland Cancer Council, 262
- queer, 328
- queer theory, 328
- racial background, 151, 152, 156, 204–205, 233, 287–288
- racial minority identities, 92
- radiation proctitis, 223
- radiotherapy: burn damage from, 289; decision making regarding, 152–157, 288–289; defined, 236, 328; late radiation effects, 292, 298–299; personal experiences, 292, 297–299; side effects of, 164, 166; as treatment option, 274–275. *See also* GBM with prostate cancer—radiotherapy vs. radical prostatectomy effects
- Rastinehad, Art, 284, 285, 286–287, 288, 289
- receptive partner (bottom), 328
- recreation, 200, 204
- rectal anatomy changes, 221, 223
- rectal irritation/pain, 24–25, 153
- rectal toxicity, 153
- Regan, T. W., 70
- rehabilitation, 328
- relationality, 328
- relationships: adjustments in, 153; configurations, 69, 106; ejaculate loss and, 55, 57; erectile dysfunction and, 39, 44–46; illness intrusiveness and, 200, 203–204, 206 *t.* 12.2, 208–212
- religious activities, 203
- Reproductive Health Matters* (journal), 258
- research literature: gaps/inconsistencies in, 39–40, 55, 69–70, 175; on GBM/HCP communication, 134–136, 135 *t.* 8.1; on GBM with prostate cancer, 12, 14 *t.* 1.1, 55–56; heteronormativity and, 100; heterosexism and, 55; inclusion/exclusion criteria in, 325; on partnerships and cancer survivorship, 69; on psychological adjustment, 87–88; qualitative studies, 16–19 *t.* 1.2, 39, 324, 328; quantitative studies, 20–23 *t.* 1.3, 39; on sexual/gender minorities, 13; on TGW, 12; on treatment outcomes, 154
- Restore Aim 1, 22 *t.* 1.3
- Restore Aim 3, 22 *t.* 1.3
- retrograde ejaculation, 299
- rimming, 165
- role-in-sex, 218, 223–224, 328
- role-play, 237
- Rose, Duncan, 75, 91, 145–146
- Rosser, B. R. Simon, 18 *t.* 1.2, 22 *t.* 1.3, 56–57, 63, 151, 201–202, 237, 306–314, 307 *fig.* 20.1
- RxSleeve, 171
- safe sex, 259
- same-sex marriage, 77, 106, 124–125, 175
- Sandoe, David, 250
- Satisfaction with Support, 204
- saturation, 328
- Schindler, Paul, 284
- Schover, L. R., 195
- seeds, 288, 294, 328. *See also* brachytherapy
- self-esteem loss, 24, 173, 220, 227

- self-expression, 203
- semen, blood in, 286, 298
- semen exchange, 39, 47, 329
- serum, 329
- sex-on-premises venues, 106, 188
- sex parties, 106
- sex roles, 329
- sexual aids/toys, 60, 105; cost of, 188, 192–193; discontinued use of, 181; GBM vs. heterosexual male use of, 180, 184–186 *t. 11.1*; GBT sexuality and, 237; HCPs and, 170; negative experiences, 188–194; physical side effects of, 188, 190–192; sexual recovery assisted through use of, 164, 167–173; successful experiences, 183–187
- sexual bother, 88, 201
- sexual disqualification, 38, 44–46, 56–57, 63–64, 173, 187; defined, 329
- sexual dysfunction, 203, 329
- sexual functioning, 3, 39, 56, 87–88, 105, 153
- sexual/gender minorities (SGM): ASCO strategies for healthcare environments for, 158–160, 159 *t. 9.1*. *See also* lesbian/gay/bisexual/transgender (LGBT) populations
- sexual health, 329
- sexual identity: disclosure of, to HCPs, 132, 133–134, 138–140, 144–145, 236–237; simplistic notions of, 111
- sexuality: HCP concerns with, in cancer treatment, 133; illness intrusiveness and, 200, 204; masculine identity and, 59; after prostate cancer, 102–103; in prostate cancer literature, 104
- sexuality, post-prostatectomy: biopsychosocial, 56–60; partnerships and, 54–55, 57–60, 63–64, 78; personal experiences, 265–266, 267, 280; role shifts, 54; sexual intimacy/erotic pleasure maintained in, 60–63; sexual losses, 54, 56–60; spontaneity lacking in, 57, 60, 167–169, 189–190, 275, 301
- sexually transmitted infections (STIs), 15, 287, 329
- sexual minorities: cancer risk factors of, 87; defined, 323; as devalued identity, 92; psychosocial research in, 232–233
- sexual minority communities, 90–91
- sexual-minority men, 69, 329. *See also* gay/bisexual men (GBM)
- sexual mode, 329
- sexual orientation, 329. *See also* sexual identity
- sexual promiscuity, 119
- sexual reassignment surgery. *See* gender-reassignment surgery
- sexual rehabilitation/recovery: as continuous process, 302; heteronormativity and, 181–182; information access regarding, 188, 193–194; partnerships and, 165, 174–175; personal experiences, 302; sexual aids/toys assisting with, 167–173; singlehood and, 173
- sexual rehabilitation/recovery—GBM vs. heterosexual men: research studies on, 180, 182–183, 194–196; sex aid use, 184–186 *t. 11.1*, 194; sexual experimentation and, 194–195; social support and, 201–202, 300–301; successful, 183–187; unsuccessful, 188–194
- sexual response cycle, 329

- sexual subcultures, 330
- sexual well-being, 330
- shared decision-making (SDM) model, 152–157, 236–237; components of, 305; defined, 305, 330; first-person case study for, 304, 306–314, 307 *fig. 20.1*, 314–315; for PSA testing, 305–306; radiotherapy vs. radical prostatectomy effects and, 229–230; strengths/weaknesses of, 304, 315–316
- Shine a Light (support group), 272, 281–282
- shock, 219, 224
- singlehood, 164, 173, 203
- skin outbreaks, 288
- Smith-Stoner, Marilyn, 72
- smoking, 87, 152, 287
- social isolation, 86, 157, 173, 209
- social marginalization, 4
- social stress, 88, 93
- social support, 24, 25; comprehensive care model for, 239–240; GBM communication about sexuality with, 134–136, 135 *t. 8.1*, 156–157; partnerships and, 200–201; personal experiences, 262, 263–264, 276–277; as quality of life indicator, 201. *See also* illness intrusiveness and social support; support groups
- Social Work Abstracts, 13
- sociodemographics, 68, 72–74
- South Africa, 175, 250
- SpareParts, 170
- spatiality, 330
- sperm donations, 279–280
- Start a Cure, 256
- steroids, 15
- stigmatization: defined, 330; fear of, 235; HIV infection and, 110; interdependence theory and, 68, 75; internalized, 4; as minority status issue, 24; minority stress theory and, 88, 90. *See also* discrimination; heterosexism; homophobia
- stress, chronic, 79, 87, 238, 287. *See also* minority stress theory
- substance use, 88–90, 92, 152, 233
- suicide, 43, 103
- support groups: access to, 212; benefits of, 239–240; emotional reactions in, 300–301; format for, 254; information seeking with, 180; personal experiences, 275, 278, 292, 299–301; Shine a Light, 272; size of, 249. *See also* Malecare
- surveillance, 330. *See also* active surveillance
- survivor/survivorship, 101, 150, 330
- tactile genital stimulation (hand job), 165
- temporality, 330
- tenesmus, 330
- testosterone supplements, 15, 287
- Tewari, Ash, 289
- Thomas, C., 17 *t. 1.2*
- tops, 92, 228, 328, 330
- Torre, Joe, 294, 296
- transformation of motivation, 76
- transgender people, 330
- transgender women (TGW): characteristics of, with prostate cancer, 168 *t. 10.1*; comprehensive care models for, 232 (*see also* GBT comprehensive prostate cancer care model); defined,

- 331; estrogen therapy and, 165–166;  
as marginalized group, 118; orgasmic  
changes in, 164, 167; prostate cancer  
risk among, 2, 12, 14, 167n; research  
literature on, 14 *t. 1.1*; sexual recovery  
of, 165, 172, 237; single, 173; support  
groups for, 251, 299; as underres-  
earched, 2, 12, 14, 151, 167, 175
- transphobia, 238
- transsexual, 331
- triadic relationships, 69
- Trump, Donald J., 124n
- tumor-nodes-metastasis (TNM) system,  
264
- ultrasound, 286, 287, 297
- United Kingdom, 40, 175, 250
- United States: cultural competency  
requirements in, 126; health  
information privacy in, 324, 326;  
Malecare collaborations in, 250;  
prostate cancer rates in, 2–3, 13–14,  
151, 259; prostate cancer-related  
suicide rate in, 103; research studies  
including citizens of, 40, 103;  
same-sex marriage legalized in  
(2015), 77, 124–125, 175
- United States Navy, 109
- United States Supreme Court, 124
- University of Rochester, 72
- urinary bleeding, 286, 293
- urinary incontinence: coping with, 62;  
defined, 331; gay identities and,  
48–49; GBM vs. heterosexual men,  
201; illness intrusiveness and, 201,  
202, 203; as prostate cancer treat-  
ment side effect, 55, 56, 153; quality of  
life considerations and, 155; radio-  
therapy vs. radical prostatectomy, 218,  
219, 220; support group discussions  
about, 301
- urinary tract infections, 305
- urology, 311–312, 331
- Ussher, Jane M., 19 *t. 1.2*, 23 *t. 1.3*, 56, 61,  
62, 63, 75, 145–146, 153, 155
- vacuum erection device (VED), 105,  
167–168, 169, 172–173, 180, 186, 193,  
331
- vaginal sex, 39, 105, 169
- vasoconstriction devices, 183. *See also*  
cock rings
- vegetarianism, 287
- versatility, 105, 181, 328, 331
- Viagra, 105, 181, 187, 190, 193, 265, 293
- Viberect (vibrator), 171
- vibrators, 171, 183
- violence, 90
- Wassersug, Richard J., 16 *t. 1.2*, 21 *t. 1.3*,  
56, 154, 155, 170
- watchful waiting. *See* active surveillance
- weight gain, 157
- Weill Cornell Medical Center, 289
- Wellington (New Zealand), 278
- What Every Gay Man Needs to Know about  
Prostate Cancer* (ed. Perlman), 295
- Wibowo, Erik, 56, 155, 170
- Wittmann, Daniela, 56, 59, 60–61, 63
- Yalom, Irvin, 300
- Young, Hugh, 284, 289
- YouTube, 172
- Zoro (dildo), 170